We serve Chemical Name:methyl 3-[4-(trifluoromethyl)phenyl]benzoate CAS:773875-92-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![methyl 3-[4-(trifluoromethyl)phenyl]benzoate](https://a.dearchem.com/CAS2/773875-92-6.png)
Chemical Name:methyl 3-[4-(trifluoromethyl)phenyl]benzoate
CAS.NO:773875-92-6
Synonyms:methyl 3-[4-(trifluoromethyl)phenyl]benzoate
Molecular Formula:C15H11F3O2
Molecular Weight:280.24200
HS Code:2916399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:26.30000
Exact Mass:280.07100
LogP:4.15900
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like methyl 3-[4-(trifluoromethyl)phenyl]benzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 3-[4-(trifluoromethyl)phenyl]benzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 3-[4-(trifluoromethyl)phenyl]benzoate Use and application,methyl 3-[4-(trifluoromethyl)phenyl]benzoate technical grade,usp/ep/jp grade.
Related News: Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday. methyl 3-[4-(trifluoromethyl)phenyl]benzoate manufacturer This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs. methyl 3-[4-(trifluoromethyl)phenyl]benzoate supplier Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%. methyl 3-[4-(trifluoromethyl)phenyl]benzoate vendor This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs. methyl 3-[4-(trifluoromethyl)phenyl]benzoate factory But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies.
